Desalting And Buffer Exchange Market Size

Desalting And Buffer Exchange Market Analysis

The global desalting and buffer exchange market is valued at USD 1.10 billion in 2023 and is expected to reach USD 1.78 billion by the year 2028, registering a CAGR of 10.1% over the forecast period (2023-2028).

The COVID-19 pandemic impacted the desalting & buffer exchange market initially. The sudden outbreak and massive numbers of COVID-19 infections created an unprecedented demand for research and development of therapeutic, vaccines, and diagnostic assays for managing COVID-19. The R&D of the COVID-19 diagnosis and therapeutics required desalting & buffer exchange products, which resulted in a hike in demand for the desalting & buffer exchange products in the downstream process amid the pandemic. Several research studies related to SARS-CoV-2 protein or nucleic acid extraction, diagnosis, and therapeutic development mentioned the use of desalting & buffer exchange products. For instance, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), in 2021, 11 billion COVID-19 vaccines were produced, and nearly 200 vaccine candidates were in the production pipeline. The desalting and buffer exchange products were extensively used in the vaccine production process as the buffer exchange is an important step in the downstream process. Thus, the pandemic had a favorable impact on the market initially; however, with the decrease in COVID-19 cases and the resumption of R&D for non-COVID-19 indications, the market is growing normally. It will continue the trend over the forecast period as well.

The increasing research and development by biopharmaceutical industries and the rising focus on proteomic and genomic research are the major drivers for the market.

The increasing demand for biopharmaceutical products, coupled with the rise in research and development expenditure on biopharmaceutical products, is one of the key drivers for the market. For instance, as per the data published by the European Federation of Pharmaceutical Industries and Associations' Annual Report 2022, the value of production for the research-based European pharmaceutical industry increased in the past years, and it reached the value of EUR 300.0 billion (USD 321.21 billion) in 2021. Such an initiative is expected to increase the production of drugs and related research works. Since desalting and buffer exchange play an important role in the downstream production process of drugs, the increasing expenditure on the research and development of biopharmaceuticals is expected to boost the market's growth over the forecast period.

Additionally, the increasing investment by the market players in the research and development of products and facilities is expected to boost the R&D and manufacturing of vaccines, which is also expected to elevate the demand for desalting and buffer exchange products in the coming years. For instance, in April 2022, Thermo Fisher Scientific opened its new single-use technology manufacturing site in Utah, the United States. The state-of-the-art facility will be more capable of manufacturing the high-quality technology and materials needed to develop new vaccines and breakthrough therapies. The facility will manufacture highly customizable bioprocess container (BPC) systems. Similarly, in December 2022, Pfizer invested over USD 750.0 million in expanding the Michigan pharmaceutical manufacturing plant in the United States to elevate the production of vaccines and medicines using mRNA technology. Hence, such investments by the market players are expected to drive the demand for purification processes of the final products, which essentially require desalting and buffer exchange products, thereby boosting the market growth over the forecast period.

Therefore, owing to the increasing investment in R&D and strategic initiatives by the key players related to the market, considerable market growth is expected over the forecast period.

However, the lack of skilled professionals may impede the market growth over the forecast period.